Could There Be a Biologically Plausible Niche for Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion Treatment in Early Onset Neonatal Septic Shock?

Pediatr Crit Care Med. 2020 Feb;21(2):202-203. doi: 10.1097/PCC.0000000000002164.

Authors

Zachary Aldewereld¹, Joseph A Carcillo

Affiliation

¹ Department of Critical Care Medicine; and Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA Department of Critical Care Medicine; and Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA.

PMID: 32032268
DOI: 10.1097/PCC.0000000000002164

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anti-Bacterial Agents
Hemoperfusion*
Humans
Infant, Newborn
Polymyxin B
Shock*
Shock, Septic*

Substances

Anti-Bacterial Agents
Polymyxin B